About 3 Worth Of Brooklyn ImmunoTherapeutics Inc. (BTX) Shares Belongs To Its 10% Owner

As of Thursday close, Brooklyn ImmunoTherapeutics Inc.’s (NASDAQ:BTX) stock was down -$0.03, moving down -3.71 percent to $0.72. The average number of shares traded per day over the past five days has been 637,860 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.2481 fall in that time frame. In the last twenty days, the average volume was 506,970, while in the previous 50 days, it was 465,924.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, BTX stock retreated -55.69%. Shares of the company fell to $0.7000 on 05/12/22, the lowest level in the past month. A 52-week high of $32.64 was reached on 01/03/22 after having rallying from a 52-week low of $0.75. Since the beginning of this year, BTX’s stock price has dropped by -82.68% or -$3.4477, and marked a new high 1 time. However, the stock has declined by -97.79% since its 52-week high.

Brooklyn ImmunoTherapeutics Inc. (BTX) last reported insider trading activity 303 days ago on Jul 14. DENNY GEORGE P III, the 10% Owner of the company, purchased of 1 shares for $11.99 on Jul 14. It resulted in a $12 investment by the insider. DENNY GEORGE P III added 1 shares at an average price of $14.11 on Jul 09. The insider now owns 2 shares following the transaction. On Jul 08, 10% Owner DENNY GEORGE P III bought 1 shares at $14.35 apiece. The transaction was valued at $14.

Financial Health

In the three months ended September 29, Brooklyn ImmunoTherapeutics Inc.’s quick ratio stood at 5.10, while its current ratio was 5.10, showing that the company is able to pay off its debt.

While analysts expected Brooklyn ImmunoTherapeutics Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.11 per share, beating the consensus estimate by -37.50%. The liabilities of Brooklyn ImmunoTherapeutics Inc. were 25.93 million at the end of its most recent quarter ended September 29, and its total debt was $3.23 million. The value of shareholders’ equity is $57.45 million.

Technical Picture

This quick technical analysis looks at Brooklyn ImmunoTherapeutics Inc.’s (BTX) price momentum. With a historical volatility rate of 30.34%, the RSI 9-day stood at 11.39% on 12 May.

With respect to its five-day moving average, the current Brooklyn ImmunoTherapeutics Inc. price is down by -25.57% percent or -$0.2481. At present, BTX shares trade -57.51% below its 20-day simple moving average and -85.64% percent below its 100-day simple moving average. However, the stock is currently trading approximately -67.90% below its SMA50 and -93.93% below its SMA200.

Stochastic coefficient K was 5.04% and Stochastic coefficient D was 6.00%, while ATR was 0.1153. Given the Stochastic reading of 3.98% for the 14-day period, the RSI (14) reading has been calculated as 14.22%. As of today, the MACD Oscillator reading stands at -0.1272, while the 14-day reading stands at -0.2012.

Analyst Ratings

Cantor Fitzgerald launched its rating on Brooklyn ImmunoTherapeutics Inc. (NASDAQ: BTX) to an Overweight in a note to investors on December 29, 2021. Brooklyn ImmunoTherapeutics Inc. (BTX) has been rated Buy by analysts. According to 0 brokerage firms, BTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Brooklyn ImmunoTherapeutics Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $4.50, the current consensus forecast for the stock is $4.00 – $5.00. Based on these forecasts, analysts predict Brooklyn ImmunoTherapeutics Inc. (BTX) will achieve an average price target of $4.50.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles